Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic-论文阅读讨论-ReadPaper - 轻松读论文 | 专业翻译 | 一键引文

DOI: 10.1161/circulationaha.121.057075

CAS-1 JCR-Q1 SCIE

Luke J. LaffinHarvey W. KaufmanZhen ChenJustin K. NilesAndre R. ArellanoLance A. BareStanley L. Hazen

Luke J. LaffinHarvey W. KaufmanZhen Chen ...+3 Stanley L. Hazen

Circulation

Jan 2022

61被引用

0笔记

摘要原文

HomeCirculationVol. 145, No. 3Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBRise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic Luke J. Laffin, Harvey W. Kaufman, Zhen Chen, Justin K. Niles, Andre R. Arellano, Lance A. Bare and Stanley L. Hazen Luke J. LaffinLuke J. Laffin Correspondence to: Luke J. Laffin, MD, Section of Preventive Cardiology, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave, Mail Code JB1, Cleveland, OH 44195. Email E-mail Address: [email protected] https://orcid.org/0000-0002-3262-792X Heart Vascular and Thoracic Institute, Cleveland Clinic, OH (L.J.L., S.L.H.). *L.J. Laffin and H.W. Kaufman contributed equally. Search for more papers by this author , Harvey W. KaufmanHarvey W. Kaufman Quest Diagnostics, Secaucus, NJ (H.W.K., Z.C., J.K.N., A.R.A., L.A.B.). *L.J. Laffin and H.W. Kaufman contributed equally. Search for more papers by this author , Zhen ChenZhen Chen Quest Diagnostics, Secaucus, NJ (H.W.K., Z.C., J.K.N., A.R.A., L.A.B.). Search for more papers by this author , Justin K. NilesJustin K. Niles Quest Diagnostics, Secaucus, NJ (H.W.K., Z.C., J.K.N., A.R.A., L.A.B.). Search for more papers by this author , Andre R. ArellanoAndre R. Arellano Quest Diagnostics, Secaucus, NJ (H.W.K., Z.C., J.K.N., A.R.A., L.A.B.). Search for more papers by this author , Lance A. BareLance A. Bare Quest Diagnostics, Secaucus, NJ (H.W.K., Z.C., J.K.N., A.R.A., L.A.B.). Search for more papers by this author and Stanley L. HazenStanley L. Hazen Heart Vascular and Thoracic Institute, Cleveland Clinic, OH (L.J.L., S.L.H.). Search for more papers by this author Originally published6 Dec 2021https://doi.org/10.1161/CIRCULATIONAHA.121.057075Circulation. 2022;145:235–237Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: December 6, 2021: Ahead of Print Hypertension affects almost half of US adults, and blood pressure (BP) control is a national public health priority.1 The coronavirus disease 2019 (COVID-19) pandemic has disrupted both daily life and routine medical care, including the treatment of chronic diseases such as hypertension. Given the unknown impact of the pandemic on BP, this study investigated changes in BP during the pandemic among participants in a US employer-sponsored wellness program.This longitudinal study included employees and their spouses/partners, from all 50 states and the District of Columbia, participating in an annual employer-sponsored wellness program operated by Quest Diagnostics. Participants were required to have BP measured by trained personnel in all 3 years analyzed (2018–2020). The annual BP changes for 2019 versus 2018, January to March 2020 versus 2019, and April to December 2020 versus 2019 were estimated for comparisons between prepandemic (January 2019–March 2020) and pandemic (April–December 2020) periods. Most US jurisdictions put in place COVID-19 stay-at-home orders between mid-March and the start of April 2020, thus establishing prepandemic and pandemic time periods. The mixed model for repeated measures was fitted to assess the adjusted effects of time (pandemic versus prepandemic), sex, and age on changes in BP. Data analyses were performed using SAS Studio 3.6 on SAS version 9.4.This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting cross-sectional studies2 and was deemed exempt by the Western Institutional Review Board in accordance with 45 CFR §160 and §164. Inquiries for data and collaboration inquiries may be directed to [email protected] or to harvey.w.[email protected]com.Of 533 645 potential participants in 2018, after applying data exclusions, 464 585 (87%) study participants remained for evaluation with valid data for each of the 3 calendar years analyzed. The cohort included 53.5% women, with a mean (SD) age of 45.7 (11.1) years in 2018.Changes from the preceding year in both systolic and diastolic BP showed no differences between 2019 and January to March 2020 (P=0.8 for systolic and P=0.3 for diastolic BP; Figure). In contrast, annual BP increase was significantly higher in April to December 2020 than 2019 (P<0.0001 for systolic and diastolic BP). During the pandemic period, mean changes each month, compared with the previous year, ranged from 1.10 to 2.50 mm Hg for systolic BP and 0.14 to 0.53 mm Hg for diastolic BP; systolic and diastolic BP increases held true for men and women and across age groups; larger increases were seen in women for both systolic and diastolic BP, in older participants for systolic BP, and in younger participants for diastolic BP (all P<0.0001).Download figureDownload PowerPointFigure. Blood pressure changes during the COVID-19 pandemic. Mean changes (with 95% CIs) in systolic and diastolic blood pressure (mm Hg) from the preceding year, by most recent month of participation, among all participants (A and B) and categorized by time period, age group, and sex (C, women; D, men). P<0.0001 for comparisons of annual changes in systolic blood pressure (mm Hg) between 2019/2018 and April to December 2020/2019 (larger), women (larger), and men, younger and older (larger), respectively; estimate of each of time period, sex, and age group in multivariate mixed model while adjusting for the other 2 factors. P=0.8 for comparisons of changes in systolic blood pressure (mm Hg) between 2019/2018 and January to March 2020/2019. P<0.0001 for comparisons of annual changes in diastolic blood pressure (mm Hg) between 2019/2018 and April to December 2020/2019 (larger), women (larger), and men, younger (larger) and older, respectively; estimate of each of time period, sex, and age group in multivariate mixed model while adjusting for the other 2 factors. P=0.3 for comparisons of changes in diastolic blood pressure (mm Hg) between 2019/2018 and January to March 2020/2019.Participants were next categorized as outlined in the 2017 American BP guidelines (normal, elevated, stage 1 hypertension, and stage 2 hypertension). In the 15-month prepandemic period, compared with the previous year, participant recategorization to a higher versus lower BP category was equivalent (chi-square test, P=0.1; 2019: 24.4% higher/23.6% lower; January–March 2020: 24.9% higher/23.8% lower). In April to December 2020, compared with the prepandemic period, a greater proportion of participants were upcategorized (26.8%) than downcategorized (22.0%; chi-square test, P<0.0001).Weight gain was not the apparent reason for the observed rise in BP during the pandemic, because an average reduction in weight in men was seen in the pandemic period (–0.2 ± 12.4 lb) and the increase in weight of women (0.6 ± 12.2 lb) was the same as the prepandemic period, in 400 067 (86%) participants with weight data in all 3 years.Small population-level increases in BP are associated with increased long-term incidence of major adverse cardiovascular events. For example, a 2-mm Hg higher systolic BP is associated with significant increases in mortality from stroke and ischemic heart disease among middle-aged adults.3 Thus, the increase in systolic BP among US adults during the COVID-19 pandemic could signal a forthcoming increase in incident cardiovascular disease mortality. Reasons for pandemic-associated BP elevations are likely multifactorial, and although weight gain was not the reason, other possible reasons could include increased alcohol consumption, less physical activity, emotional stress, and less ongoing medical care (including reduced medication adherence).4 The finding of greater BP increases in women, compared with men, provides more evidence of the outsized burden that pandemics place on women.5 Although the current cohort is large and includes adults, primarily of middle age, from all 50 states, whether it serves as a representative of US adults is unknown.Continued surveillance of BP among US adults after the pandemic is needed to assess the permanence of the increases noted here. Public health interventions reinforcing the need to address chronic medical problems, even during a pandemic, remain crucial.Article InformationAcknowledgmentsL.J.L. and H.W.K. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors made the following contributions: concept and design, L.J.L., H.W.K., and S.L.H.; acquisition, analysis, or interpretation of data, L.J.L., H.W.K., S.L.H., J.K.N., Z.C., A.R.A., and L.A.B.; drafting of the article, L.J.L. and H.W.K.; critical revision of the article for important intellectual content, all authors; statistical analysis, Z.C., A.R.A., and J.K.N.; and administrative, technical, or material support, H.W.K. and S.L.H.Sources of FundingS.L.H. is supported by grant P01 HL147823 from the National Institutes of Health and the Office of Dietary Supplements. The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; and decision to submit the article for publication.DisclosuresDr Hazen reports having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Laboratory, a fully owned subsidiary of Quest Diagnostics, and Procter & Gamble. Dr Hazen is a paid consultant for Procter & Gamble and Zehna Therapeutics and has received research funds from Proctor & Gamble, Zehna Therapeutics, Pfizer Inc, and Roche Diagnostics. Dr Laffin is a paid consultant for Medtronic and medical advisor for LucidAct Health. Dr Kaufman, J.K. Niles, Z. Chen, Dr Bare, and A.R. Arellano are employees of Quest Diagnostics, and Dr Kaufman, Z. Chen, Dr Bare, and A.R. Arellano own stock in Quest Diagnostics.Footnotes*L.J. Laffin and H.W. Kaufman contributed equally.For Sources of Funding and Disclosures, see page 237.Correspondence to: Luke J. Laffin, MD, Section of Preventive Cardiology, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave, Mail Code JB1, Cleveland, OH 44195. Email [email protected]orgReferences1. Adams JM, Wright JS. A national commitment to improve the care of patients with hypertension in the US.JAMA. 2020; 324:1825–1826. doi: 10.1001/jama.2020.20356CrossrefMedlineGoogle Scholar2. von Elm E, Altman DG, Egger M, Poco*ck SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.Ann Intern Med. 2007; 147:573–577. doi: 10.7326/0003-4819-147-8-200710160-00010CrossrefMedlineGoogle Scholar3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.Lancet. 2002; 360:1903–1913. doi: 10.1016/s0140-6736(02)11911-8CrossrefMedlineGoogle Scholar4. Czeisler MÉ, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, Ali N, McMillan H, Wiley JF, Weaver MD, et al. Delay or avoidance of medical care because of COVID-19-related concerns - United States, June 2020.MMWR Morb Mortal Wkly Rep. 2020; 69:1250–1257. doi: 10.15585/mmwr.mm6936a4CrossrefMedlineGoogle Scholar5. Wenham C, Smith J, Davies SE, Feng H, Grépin KA, Harman S, Herten-Crabb A, Morgan R. Women are most affected by pandemics - lessons from past outbreaks.Nature. 2020; 583:194–198. doi: 10.1038/d41586-020-02006-zCrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wojciechowska W, Rajzer M, Weber T, Prejbisz A, Dobrowolski P, Ostrowska A, Bilo G, Mancia G, Kreutz R and Januszewicz A (2023) Ambulatory blood pressure monitoring in treated patients with hypertension in the COVID-19 pandemic - The study of European society of hypertension (ESH ABPM COVID-19 study), Blood Pressure, 10.1080/08037051.2022.2161998, 32:1, Online publication date: 31-Dec-2024. Shibata S, Kobayashi K, Tanaka M, Asayama K, Yamamoto E, Nakagami H, Hoshide S, Kishi T, Matsumoto C, Mogi M, Morimoto S, Yamamoto K, Mukoyama M, Kario K, Node K and Rakugi H (2022) COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19, Hypertension Research, 10.1038/s41440-022-01134-5, 46:3, (589-600), Online publication date: 1-Mar-2023. Vosko I, Zirlik A and Bugger H (2023) Impact of COVID-19 on Cardiovascular Disease, Viruses, 10.3390/v15020508, 15:2, (508) Oddo V, Jones-Smith J and Knox M (2023) Changes in Precarious Employment and Health in the United States Amidst the COVID-19 Pandemic, Preventive Medicine Reports, 10.1016/j.pmedr.2023.102113, 31, (102113), Online publication date: 1-Feb-2023. Laffin L, Briasoulis A and Bakris G (2023) Newer alternatives for resistant hypertension: Beyond 2022 paradigms, Hellenic Journal of Cardiology, 10.1016/j.hjc.2023.01.006, Online publication date: 1-Feb-2023. Chen H, Peng J, Wang T, Wen J, Chen S, Huang Y and Zhang Y (2023) Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic, Biochemical Pharmacology, 10.1016/j.bcp.2022.115370, 208, (115370), Online publication date: 1-Feb-2023. Onea C, Erőss Á, Roiban A and Cernea S (2023) The metabolic control and laboratory evaluation in patients with type 2 diabetes during the COVID-19 pandemic and the impact of telemedicine: a single-center experience, Revista Romana de Medicina de Laborator, 10.2478/rrlm-2023-0002, 31:1, (43-50), Online publication date: 1-Jan-2023., Online publication date: 1-Jan-2023. Liu H, Gu T, Shojafar M, Alazab M and Liu Y OPERA: Optional Dimensional Privacy-Preserving Data Aggregation for Smart Healthcare Systems, IEEE Transactions on Industrial Informatics, 10.1109/TII.2022.3192037, 19:1, (857-866) Dale C, Takhar R, Carragher R, Katsoulis M, Torabi F, Duffield S, Kent S, Mueller T, Kurdi A, Le Anh T, McTaggart S, Abbasizanjani H, Hollings S, Scourfield A, Lyons R, Griffiths R, Lyons J, Davies G, Harris D, Handy A, Mizani M, Tomlinson C, Thygesen J, Ashworth M, Denaxas S, Banerjee A, Sterne J, Brown P, Bullard I, Priedon R, Mamas M, Slee A, Lorgelly P, Pirmohamed M, Khunti K, Morris A, Sudlow C, Akbari A, Bennie M, Sattar N and Sofat R (2023) The impact of the COVID-19 pandemic on cardiovascular disease prevention and management, Nature Medicine, 10.1038/s41591-022-02158-7, 29:1, (219-225), Online publication date: 1-Jan-2023. Kario K, Mahfoud F, Kandzari D, Townsend R, Weber M, Schmieder R, Tsioufis K, Poco*ck S, Brar S, Hettrick D, Fahy M and Böhm M (2022) Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial, Hypertension Research, 10.1038/s41440-022-01042-8, 46:1, (280-288), Online publication date: 1-Jan-2023. Whitsel L, Ajenikoko F, Chase P, Johnson J, McSwain B, Phelps M, Radcliffe R and fa*ghy M (2023) Public policy for healthy living: How COVID-19 has changed the landscape, Progress in Cardiovascular Diseases, 10.1016/j.pcad.2023.01.002, Online publication date: 1-Jan-2023. Sreedhara M, Suvada K, Bostic M, Scott A, Blum E, Jordan J and Beasley K (2022) Rapid Evaluations of Telehealth Strategies to Address Hypertension: A Mixed-Methods Exploration at Two US Health Systems During the COVID-19 Pandemic, Preventing Chronic Disease, 10.5888/pcd19.220219, 19 Gotanda H, Liyanage-Don N, Moran A, Krousel-Wood M, Green J, Zhang Y and Nuckols T (2022) Changes in Blood Pressure Outcomes Among Hypertensive Individuals During the COVID-19 Pandemic: A Time Series Analysis in Three US Healthcare Organizations, Hypertension, 79:12, (2733-2742), Online publication date: 1-Dec-2022. Egan B, Sutherland S, Macri C, Deng Y, Gerelchuluun A, Rakotz M and Campbell S (2022) Association of Baseline Adherence to Antihypertensive Medications With Adherence After Shelter-in-Place Guidance for COVID-19 Among US Adults, JAMA Network Open, 10.1001/jamanetworkopen.2022.47787, 5:12, (e2247787) Kodsi M and Bhat A (2022) Temporal trends in cardiovascular care: Insights from the COVID-19 pandemic, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.981023, 9 Cruz T, Boursaw B, Barqawi Y, FitzGerald C, Enoah N, Hayes A and Caswell L (2022) Community–Clinical Linkages: The Effects of the Healthy Here Wellness Referral Center on Chronic Disease Indicators Among Underserved Populations in New Mexico, Health Promotion Practice, 10.1177/15248399221111191, 23:1_suppl, (164S-173S), Online publication date: 1-Nov-2022. Jaeger B, Bress A, Bundy J, Cheung A, Cushman W, Drawz P, Johnson K, Lewis C, Oparil S, Rocco M, Rapp S, Supiano M, Whelton P, Williamson J, Wright J, Reboussin D and Pajewski N (2022) Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control, JAMA Cardiology, 10.1001/jamacardio.2022.3345, 7:11, (1138), Online publication date: 1-Nov-2022. Karagiannidis A, Theodorakopoulou M, Ferro C, Ortiz A, Soler M, Halimi J, Januszewicz A, Persu A, Kreutz R and Sarafidis P (2022) Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications, Clinical Kidney Journal, 10.1093/ckj/sfac235 Delgado-Floody P, Chirosa-Ríos L, Guzmán-Guzmán I, Vargas C, Sandoval-Aguilera K, Caamaño-Navarrete F, Guede-Rojas F and Alvarez C (2022) The Social Distance Impacts from COVID-19 Pandemic on the Development of Two Orders of a Concurrent Training Programme for Morbidly Obese Patients, International Journal of Environmental Research and Public Health, 10.3390/ijerph192013408, 19:20, (13408) Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T, Scicli A, Thackeray L, Azizi M and Weber M (2022) Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial, EuroIntervention, 10.4244/EIJ-D-22-00305, 18:8, (e677-e685) Barake F, Paccot M, Rivera M, Neira C, Reyes V and Escobar M (2022) Chile’s public healthcare sector hypertension control rates before and during the pandemic and HEARTS implementation, Revista Panamericana de Salud Pública, 10.26633/RPSP.2022.126, 46, (1), Online publication date: 2-Sep-2022. Muntner P, Miles M, Jaeger B, Hannon III L, Hardy S, Ostchega Y, Wozniak G and Schwartz J (2022) Blood Pressure Control Among US Adults, 2009 to 2012 Through 2017 to 2020, Hypertension, 79:9, (1971-1980), Online publication date: 1-Sep-2022. Ito S, Kobayashi K, Chin K, Umezawa S, Yamamoto H, Nakano S, Takada N, Hatori N and Tamura K (2022) Impact of the first announced state of emergency owing to coronavirus disease 2019 on stress and blood pressure levels among patients with type 2 diabetes mellitus in Japan, Journal of Diabetes Investigation, 10.1111/jdi.13813, 13:9, (1607-1616), Online publication date: 1-Sep-2022. Mousa S, Nyberg F, Hajiebrahimi M, Bertilsson R, Nåtman J, Santosa A and Wettermark B (2022) Initiation of antihypertensive drugs to patients with confirmed COVID‐19—A population‐based cohort study in Sweden, Basic & Clinical Pharmacology & Toxicology, 10.1111/bcpt.13766, 131:3, (196-204), Online publication date: 1-Sep-2022. Satoh M, Murakami T, Obara T and Metoki H (2022) Time-series analysis of blood pressure changes after the guideline update in 2019 and the coronavirus disease pandemic in 2020 using Japanese longitudinal data, Hypertension Research, 10.1038/s41440-022-00961-w, 45:9, (1408-1417), Online publication date: 1-Sep-2022. Roth G, Vaduganathan M and Mensah G (2022) Impact of the COVID-19 Pandemic on Cardiovascular Health in 2020, Journal of the American College of Cardiology, 10.1016/j.jacc.2022.06.008, 80:6, (631-640), Online publication date: 1-Aug-2022. Kolkailah A, Riggs K, Navar A and Khera A (2022) COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave, Current Atherosclerosis Reports, 10.1007/s11883-022-01033-7, 24:8, (607-617), Online publication date: 1-Aug-2022. Del Pinto R, Grassi G, Muiesan M, Borghi C, Carugo S, Cicero A, Di Meo L, Iaccarino G, Minuz P, Mulatero P, Mulè G, Parati G, Pucci G, Salvetti M, Sarzani R, Savoia C, Sechi L, Tocci G, Volpe M, Vulpis V and Ferri C (2022) World Hypertension Day 2021 in Italy: Results of a Nationwide Survey, High Blood Pressure & Cardiovascular Prevention, 10.1007/s40292-022-00519-4, 29:4, (353-359), Online publication date: 1-Jul-2022. Gordon Patti K and Kohli P (2022) COVID’s Impact on Non-communicable Diseases: What We Do Not Know May Hurt Us, Current Cardiology Reports, 10.1007/s11886-022-01704-6, 24:7, (829-837), Online publication date: 1-Jul-2022. Adji A (2022) Out-of-Office Blood Pressure: The Road Toward Improving Detection of Hypertension, American Journal of Hypertension, 10.1093/ajh/hpac029, 35:6, (506-509), Online publication date: 16-Jun-2022. Baratta J, Brown-Johnson C, Safaeinili N, Goldman Rosas L, Palaniappan L, Winget M and Mahoney M (2022) Patient and Health Professional Perceptions of Telemonitoring for Hypertension Management: Qualitative Study, JMIR Formative Research, 10.2196/32874, 6:6, (e32874) Tomidokoro D and Hiroi Y (2022) Cardiovascular considerations during the COVID-19 pandemic: A focused review for practice in Japan, Global Health & Medicine, 10.35772/ghm.2022.01006, 4:2, (101-107), Online publication date: 30-Apr-2022. Greenwood-Hickman M, Zhou J, Cook A, Mettert K, Green B, McClure J, Arterburn D, Florez-Acevedo S and Rosenberg D (2022) Exploring Differences in Older Adult Accelerometer-Measured Sedentary Behavior and Resting Blood Pressure Before and During the COVID-19 Pandemic, Gerontology and Geriatric Medicine, 10.1177/23337214221096007, 8, (233372142210960), Online publication date: 1-Apr-2022. Ilich J, Liu P, Shin H, Kim Y and Chi Y (2022) Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women, Nutrients, 10.3390/nu14051082, 14:5, (1082) Mancia G, Rea F, Grassi G, Kjeldsen S, Kreutz R and Corrao G (2022) COVID-19 and Antihypertensive Treatment Cardiovascular Complications of COVID-19, 10.1007/978-3-031-15478-2_18, (303-316), . January 18, 2022Vol 145, Issue 3 Advertisem*nt Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.121.057075PMID: 34865499 Originally publishedDecember 6, 2021 Keywordsblood pressurerisk factorshigh blood pressurePDF download Advertisem*nt SubjectsBlood PressureHigh Blood Pressure

展开全部

机器翻译

AI理解论文&经典十问

参考文献

被引用

社区问答

参考文献

发布时间 · 被引用数 · 默认排序

被引用

发布时间 · 被引用数 · 默认排序

社区问答

领域

· Internal medicine· Virology· Intensive care medicine· Emergency medicine· Outbreak· Disease· Blood pressure· Medicine

Rise in Blood Pressure Observed Among US Adults During the COVID-19 Pandemic-论文阅读讨论-ReadPaper - 轻松读论文 | 专业翻译 | 一键引文 | 图表同屏 (2024)